Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer

• Published in: Nature reviews. Urology Vol. 21; no. 5; p. 290
• Main Authors: Séguier, Denis, Adams, Eric S, Kotamarti, Srinath, D'Anniballe, Vincent, Michael, Zoe D, Deivasigamani, Sriram, Olivier, Jonathan, Villers, Arnauld, Hoimes, Christopher, Polascik, Thomas J
• Format: Journal Article
• Language: English
• Published: England 01.05.2024
• Subjects: Ablation Techniques - methods; Combined Modality Therapy; Humans; Immunotherapy - methods; Male; Prostatic Neoplasms - therapy
• ISSN: 1759-4820
• DOI: 10.1038/s41585-023-00834-y

Major advances have been made in the use of immunotherapy for the treatment of solid tumours, including the use of intratumourally injected immunotherapy instead of systemically delivered immunotherapy. The success of immunotherapy in prostate cancer treatment has been limited to specific populations with advanced disease, which is thought to be a result of prostate cancer being an immunologically 'cold' cancer. Accordingly, combining intratumoural immunotherapy with other treatments that would increase the immunological heat of prostate cancer is of interest. Thermal ablation therapy is currently one of the main strategies used for the treatment of localized prostate cancer and it causes immunological activation against prostate tissue. The use of intratumoural immunotherapy as an adjunct to thermal ablation offers the potential to elicit a systemic and lasting adaptive immune response to cancer-specific antigens, leading to a synergistic effect of combination therapy. The combination of thermal ablation and immunotherapy is currently in the early stages of investigation for the treatment of multiple solid tumour types, and the potential for this combination therapy to also offer benefit to prostate cancer patients is exciting.